About Milo Biotechnology

Milo Biotechnology is a company developing a therapy that increases muscle strength or decreases the rate of muscle atrophy for rare muscular dystrophies.

The company’s technology, a gene therapy-based on up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital (Columbus, OH).

In 2015 the therapy completed a Phase I/II clinical study in Becker Muscular Dystrophy establishing initial safety and efficacy and is currently in clinical studies for inclusion body myositis and Duchenne muscular dystrophy.

Recent News

09Apr

First Duchenne Muscular Dystrophy Patient Treated in Follistatin Gene Therapy Trial

0 Comments
First Duchenne Muscular Dystrophy Patient Treated in Follistatin Gene Therapy Trial Cleveland and Columbus, OH, April 9, 2015–Milo Biotechnology announced... Read More →
03Dec

Milo Biotechnology Announces Patent Issuance

0 Comments
Cleveland and Columbus, OH, December 3, 2014–Milo Biotechnology, which is applying its follistatin gene writing essay therapy in three clinical... Read More →
Back to Top